- FDA delayed decision on AstraZeneca’s Etcamah, allowing updated pivotal trial data showing reduced risk of progression or death versus standard care; study continues to evaluate survival benefit.
- AstraZeneca (AZN) will report Q2 2026 results on July 27 for quarter ended June 30. Three analysts project $2.54 EPS and $15.463B revenue, per LSEG data.
- AstraZeneca (AZN) will report late-stage oncology results this year: SERENA-4 (breast cancer) and AVANZAR (lung cancer). Traders watch trial outcomes, timelines and potential share impact.
TradingView
Key facts: FDA Delays Etcamah; AZN Q2 Results Jul 27; Oncology Readouts
- Sources
- TradingView
- Active symbols
- LSE:AZN
- Language
- English (India)
FDA delayed decision on AstraZeneca’s Etcamah, allowing updated pivotal trial data showing reduced risk of progression or death versus standard care; study continues to evaluate su